Bexxar tositumomab iodine-131 labeled anti-CD20 monoclonal antibody regulatory update

The FDA extended by up to three months its review of Corixa's Bexxar radioimmunotherapy for non-Hodgkin's

Read the full 160 word article

How to gain access

Continue reading with a
two-week free trial.